What benefits can lixisenatide provide when added to basal insulin regimen?

Empagliflozin might not only decrease the risk of cardiovascular events in patients with type 2, but also renal events.

Could GLP-1 inhibitors be a useful adjunct therapy in type I diabetes?

In Part 2 of this exclusive interview, Dr. Robert Geho discusses the Phase 2b study which focuses on adding Diasome's HDV to a leading pre-meal fast acting analogue.

In part one of this exclusive interview, Dr. Robert Geho discusses the essential role of the liver in metabolizing insulin, and asks why we hear about the artificial pancreas all the time, but never hear anyone talk about an artificial liver?

Do you agree that CGMS will eventually replace glucose monitors? Follow the link to share your opinion!

Here's another test of your graph-interpreting skills! Follow the link to see this graph at full size and indicate the parameter that best describes Curve 3. 1. Insulin Secretion 2. Postprandial glucose 3. Fasting glucose 4. Insulin Resistance

In this Exclusive Interview, Dr. Robert Geho joins Diabetes in Control publisher Steve Freed at the 2016 Diabetes Symposium in Boston to discuss the testing, affects, and potential marketing of a new insulin delivery system currently undergoing trials. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. …

In Part 7, the final installment of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the potential marketing and timing of the product offering. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the …

In Part 6 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho and Diabetes in Control publisher Steve Freed discuss the possible reduction in the use of insulin as well  as hypoglycemia following the use of the product. Robert Geho, MD, is a co-founder and CEO …